Emerging mechanisms of enzalutamide resistance in prostate cancer.
about
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Targeting molecular resistance in castration-resistant prostate cancerEpigenetic modulators as therapeutic targets in prostate cancerSelective glucocorticoid receptor-activating adjuvant therapy in cancer treatmentsCotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsCo-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer.ELF5-Mediated AR Activation Regulates Prostate Cancer Progression.Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Synergistic action of image-guided radiotherapy and androgen deprivation therapy.Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.The evolving role of enzalutamide on the treatment of prostate cancer.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1.Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.Inhibition of the Wnt/β-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer.Identification of Triptophenolide from Tripterygium wilfordii as a Pan-antagonist of Androgen Receptor.LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion
P2860
Q26774221-385EFEA3-2EEE-40CE-A54A-6A72524FDB24Q26795445-BE2EDBFF-3DEE-4905-A83C-5EF3C688C27DQ28071912-8AA419AC-EB06-4576-A7D8-CDA3D0BEC715Q28078896-80042625-BE0F-4CF2-9D14-D2640BF3E0FEQ30276399-C74A7F22-32EF-479F-A9CA-16F25E012750Q34484835-75AAC31C-62FC-4408-9A14-54FAC0CB8138Q35612095-D94F50BB-3BE5-4C5A-BC24-50486C7DB213Q35740095-5318C675-67AC-464E-917B-23961BBE2914Q36905832-5DBED27E-5EE7-47F4-87A1-AB62C9AFD5C1Q37008469-AA941B2A-76AC-4D62-86D2-2B39F5A6A7E1Q37508596-B3F3C9F4-1ADF-4F4E-ABD9-B45A2FBF6582Q37665251-7D7C940B-9951-4A2C-9462-E5E7D3ECC1FFQ37673863-889219DF-950E-4E2F-AE09-FD06D276583AQ37695373-A4655564-0515-419C-B057-F11C7A6CD4D6Q37705831-5AFA3FEC-8F83-4F88-88CB-218349C5F7B5Q37709535-69B57EB7-8D34-4363-BA97-A4EBF717426BQ38387844-0996A9D1-BF0E-4A93-9231-2261EBD5FBC3Q38541877-A043907E-A7F0-41E4-AB10-17922EC98815Q38661520-5435CCE0-31BD-4C08-BF2A-048C613B7A60Q38720976-B4A264F6-3B75-4E8F-976D-48C097B673D9Q39438805-997F5724-5888-40B9-B79E-2636E494EDA7Q47197872-B7C84B1A-0D01-425E-9A82-4C43629262B8Q48103261-B6CA14C0-151D-4C5C-B15B-E63508A9210EQ52615484-1F3EF7E3-A6EC-4FF1-9B91-31167F2BEC9FQ53691090-72444EE0-840C-468A-B800-296008445A55Q54296578-A6AE3D9E-FCEC-4E2F-A957-54211022CAE1Q55010012-61A6CC7D-FED4-4E52-8D1D-479187DCB4EEQ57910094-7FDC4DA0-E077-4BDB-8A83-3CE5AA0FBBD2
P2860
Emerging mechanisms of enzalutamide resistance in prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Emerging mechanisms of enzalutamide resistance in prostate cancer.
@en
Emerging mechanisms of enzalutamide resistance in prostate cancer.
@nl
type
label
Emerging mechanisms of enzalutamide resistance in prostate cancer.
@en
Emerging mechanisms of enzalutamide resistance in prostate cancer.
@nl
prefLabel
Emerging mechanisms of enzalutamide resistance in prostate cancer.
@en
Emerging mechanisms of enzalutamide resistance in prostate cancer.
@nl
P2093
P2860
P50
P356
P1476
Emerging mechanisms of enzalutamide resistance in prostate cancer
@en
P2093
Christine Helsen
Frank Claessens
Hendrik Van Poppel
Lien Spans
P2860
P2888
P304
P356
10.1038/NRUROL.2014.243
P407
P577
2014-09-16T00:00:00Z
P5875
P6179
1029758531